Updated on 3 May 2012
Tibotec is a pharmaceutical company that was established in 1994 by Rudi Pauwels as a drug discovery laboratory and was acquired by Johnson & Johnson in 2002, has been involved in the development of TMC207. This is the first TB compound with a new mechanism of action in 40 years.
Otsuka, Japan, was established in 1964, has been screening TB compounds for about 25 years. The company's OPC-67683 has been in clinical development for about three years.
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
